Growth Metrics

Rigel Pharmaceuticals (RIGL) Net Margin (2010 - 2026)

Rigel Pharmaceuticals' quarterly Net Margin came in at 14.71% in Q1 2026, down 675.0% year-on-year from 2.56% in Q1 2025, and down 96.17% quarter-over-quarter from 384.04% in Q4 2025.

Rigel Pharmaceuticals has reported Net Margin for 16 years, with the latest figure at 14.71% in Q1 2026.

  • For the quarter ending Q1 2026, Net Margin fell 675.0% year-over-year to 14.71%; the trailing twelve-month figure through Mar 2026 stood at 121.51% (up 10320.0% YoY), and the FY2025 full-year result was 124.72%, up 11497.0% from the prior year.
  • Net Margin for Q1 2026 stood at 14.71%, down from 384.04% in the prior quarter.
  • The five-year high for Net Margin was 384.04% in Q4 2025, with the low at 164.0% in Q1 2022.
  • Average Net Margin over 5 years is 8.8%, with a median of 2.06% recorded in 2023.
  • Year-over-year, Net Margin tumbled 21275 bps in 2022 and jumped 35914 bps in 2025.
  • Tracing RIGL's Net Margin over 5 years: stood at 2.73% in 2022, then fell by 25 bps to 2.06% in 2023, then soared by 1109 bps to 24.9% in 2024, then jumped by 1442 bps to 384.04% in 2025, then tumbled by 96 bps to 14.71% in 2026.
  • The last three Net Margin figures came in at 14.71% (Q1 2026), 384.04% (Q4 2025), and 40.17% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.82%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 34.53%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 20.17%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.65%
10 Rigel Pharmaceuticals 551.62 Mn 404.94 Mn 54.21 Mn 14.71%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 14.71%
Dec 31, 2025 384.04%
Sep 30, 2025 40.17%
Jun 30, 2025 58.63%
Mar 31, 2025 21.46%
Dec 31, 2024 24.90%
Sep 30, 2024 22.46%
Jun 30, 2024 -2.80%
Mar 31, 2024 -27.92%
Dec 31, 2023 2.06%
Sep 30, 2023 -20.23%
Jun 30, 2023 -24.55%
Mar 31, 2023 -51.92%
Dec 31, 2022 2.73%
Sep 30, 2022 -84.95%
Jun 30, 2022 -45.25%
Mar 31, 2022 -164.00%
Dec 31, 2021 -110.74%
Sep 30, 2021 -97.26%
Jun 30, 2021 -52.62%
Mar 31, 2021 48.75%
Dec 31, 2020 -104.27%
Sep 30, 2020 -77.08%
Jun 30, 2020 -109.71%
Mar 31, 2020 38.10%
Dec 31, 2019 -111.69%
Sep 30, 2019 -55.09%
Jun 30, 2019 -198.00%
Mar 31, 2019 -139.40%
Dec 31, 2018 8.53%
Sep 30, 2018 -488.51%
Jun 30, 2018 -1,430.16%
Dec 31, 2017 576.96%
Sep 30, 2017 -1,962.22%
Mar 31, 2017 -427.29%
Dec 31, 2016 -519.67%
Sep 30, 2016 -601.84%
Jun 30, 2016 -157.47%
Mar 31, 2016 -347.27%
Dec 31, 2015 -148.61%
Sep 30, 2015 -51.34%
Jun 30, 2015 -268.36%
Mar 31, 2015 -835.31%
Dec 31, 2013 -293.23%
Jun 30, 2013 -1,626.29%
Jun 30, 2012 -1,649.20%
Mar 31, 2012 -3,089.87%
Sep 30, 2011 -411.73%
Jun 30, 2011 -5,436.46%
Sep 30, 2010 69.77%
Jun 30, 2010 54.65%